| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000031693 |
| Receipt No. | R000036196 |
| Public title | Evaluation of the efficacy of dietary fiber-containing food on gastrointestinal condition : a double blind, randomized, placebo controlled, crossover study |
| Date of disclosure of the study information | 2018/03/13 |
| Last modified on | 2019/03/13 (Ver. 3) |
| Basic information | ||
| Public title | Evaluation of the efficacy of dietary fiber-containing food on gastrointestinal condition : a double blind, randomized, placebo controlled, crossover study | |
| Acronym | Evaluation of the efficacy of dietary fiber-containing food on gastrointestinal condition | |
| Scientific Title | Evaluation of the efficacy of dietary fiber-containing food on gastrointestinal condition : a double blind, randomized, placebo controlled, crossover study | |
| Scientific Title:Acronym | Evaluation of the efficacy of dietary fiber-containing food on gastrointestinal condition | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluation of the efficacy of the dietary fiber-containing food on gastrointestinal condition |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Number and ratio of fecal Bifidobacterium
Defecation frequency |
| Key secondary outcomes | Defecation days, stool volume, stool shape, stool color, stool smell and the feeling after defecation
Intestinal microflora analysis Fecal ammonia measurement Fecal pH measurement Fecal water content measurement Stool weight |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Taking a control food for 14 days -> Washout period for 21 days -> Taking a test food at low dose for 14 days -> Washout period for 21 days -> Taking a test food at high dose for 14 days | |
| Interventions/Control_2 | Taking a test food at low dose for 14 days -> Washout period for 21 days -> Taking a test food at high dose for 14 days -> Washout period for 21 days -> Taking a control food for 14 days | |
| Interventions/Control_3 | Taking a test food at high dose for 14 days -> Washout period for 21 days -> Taking a control food for 14 days -> Washout period for 21 days -> Taking a test food at low dose for 14 days | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)Healthy males and females from 20 to 64 years old
2)Subjects with defecation at three to five times per week 3)Subjects with fewer number and lower ratio of Bifidobacterium in feces 4)Subjects who have received written informed consent |
|||
| Key exclusion criteria | 1) Subjects who regularly use laxatives
2) Subjects who regularly take foods which may affect gastrointestinal condition 3) Subjects who regularly use antibiotics and other medicines which affect digestion and absorption 4) Subjects who cannot abstain from taking foods which are containing viable bacteria, enriched with oligosaccharides or dietary fiber, considered effective for constipation improvement and are containing large amount of sugar alcohol 5) Subjects who have allergy for foods 6) Subjects who regularly take too much alcohol 7) Subjects who have diseases which require urgent treatment or severe complications 8) Subjects who have gastrointestinal diseases or a surgical history which may affect digestion, absorption and defecation 9) Subjects who are pregnant, lactating or planning to be pregnant in the test period 10) Subjects who are under treatment or have a history of drug addiction or alcoholism 11) Subjects who are participating or planning to participate in a clinical study 12) Subjects who are judged as inappropriate by investigator |
|||
| Target sample size | 45 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Shinagawa Season Terrace Health Care Clinic | ||||||
| Division name | Medical examination and treatment management family chief director | ||||||
| Zip code | |||||||
| Address | 1-2-70, Konan, Minato-ku, Tokyo The 5th floor of Shinagawa season terrace | ||||||
| TEL | 03-3452-3381 | ||||||
| satoru_suzuki@sempos.or.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | KSO Corporation | ||||||
| Division name | Sales department | ||||||
| Zip code | |||||||
| Address | 1-9-7, Shibaura, Minato-ku, Tokyo The 7th floor of Shibaura omodaka building | ||||||
| TEL | 03-3452-7733 | ||||||
| Homepage URL | |||||||
| yoshi@kso.co.jp | |||||||
| Sponsor | |
| Institute | KSO Corporation |
| Institute | |
| Department | |
| Funding Source | |
| Organization | KOBAYASHI Pharmaceutical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036196 |